Pharmacokinetics of 5-fluorouracil in mutant Nagase analbuminemic rats: Faster metabolism of 5-fluorouracil via CYP1A

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 2, 2007, Pages 87-95

  Choi, Young H ^a   Bae, Soo K ^a   Kim, Sun O ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Samyang Corporation   (South Korea)

Author keywords

5 flourouracil; CYP1A; Mutant Nagase analbuminemic rats; Time averaged nonrenal clearance

Indexed keywords

3 METHYLCHOLANTHRENE; ALBUMIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; FLUOROURACIL; PROADIFEN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STABILITY; GENE EXPRESSION; MALE; MUTANT; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

ACETYLGLUCOSAMINIDASE; ANIMALS; ANTIMETABOLITES; AREA UNDER CURVE; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; FLUOROURACIL; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; METHYLCHOLANTHRENE; MICRODIALYSIS; PROADIFEN; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN;

EID: 33947367810     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.534     Document Type: Article

References (34)

1. Okajima K, Inoue M, Itoh K, Nagase S, Morino Y. Role of albumin in renal elimination of a mercapturic acid: analyses in normal and mutant analbuminemic rats. Eur J Biochem 1985; 50: 195-199.
2. Inoue M, Koyama H, Nagase S, Morino Y. Renal secretion of phenolsulfonpthalein: analysis of its vectorial transport in normal and mutant analbuminemic rats. J Lab Clin Med 1985; 105: 484-488.
3. Inoue M, Koyama H, Nagase S, Morino Y. Hepato-renal transport of phenolsulfophthalein in analbuminemic rats: albumin is essential for hepatic compensatory elimination of a nephrophilic ligand in animals with renal dysfunction. J Biochem 1986; 100: 201-206.
4. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987; 32: 198-203.
5. Thummel KE, Shen DD, Isoherranen N, Smith HE. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th edn), Brunton LL, Lazo JS, Parker KL (eds). McGraw-Hill: Medical Publishing Division, New York, 2006; 1827.
6. Tomonori T, Hironori N, Minoru W, Masami T, Toshio K, Shinichi K. Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity. Clin Chim Acta 1996; 52: 1-9.
7. Peters GJ, van Groeningen CJ, Laurensse EJ, Pinedo HM. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991; 68: 1903-1909.
8. Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol 2003; 59: 407-409.
9. Yoshisue K, Nagayama S, Shindo T, Kawaguchi Y. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther 2001; 297: 1166-1175.
10. Kim EJ, Lee AK, Kim SH, Kim SG, Lee MG. Pharmacokinetics and pharmcodynamics of intravenous azosemide in mutant Nagase analbuminemic rats. Drug Metab Dispos 2003; 31: 194-201.
11. Exsborg S, Ehrsson H, Ekqvist B. Protein binding of anthraquinone glycosides, with special reference to adriamycin. cancer Chemother Pharmacol 1982; 10: 7-10.
12. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status- in pancreatic cancer patients. Anticancer res 2001; 21: 1355-1358.
13. Correia MA. Appendix B. Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functional markers. In Cytochrome P450. Structure, Mechanism, and Biochemistry (2nd edn), Oritz de Montellano PR (ed). Plenum Press: New York and London, 1995; 607-630.
14. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
15. Jarugula VR, Lam SS, Boudinot FD. Nonlinear pharmacokinetics of 5-fluorouracil in rats. J Pharm Sci 1997; 86: 756-758.
16. Loos WJ, Bruijin PD, Zuylen LV, et al. Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography. J Chromatogr B 1999; 735: 293-297.
17. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
18. Chu DF, Gu JK, Liu WH, Fawcett JP, Dong QG. Sensitive liquid chromatographic assay for the simultaneous determination of 5-fluorouracil and its prodrug, tegafur, in beagle dog plasma. J Chromatogr B 2003; 795: 377-382.
19. Conney AH. Environmental factors influencing drug metabolism. In Fundamentals of Drug Metabolism and Drug Disposition, La Du BN, Mandel HG, Way EL (eds). Williams & Wilkins Company: Baltimore, 1971; 269.
20. Williams JF, Lowitt S, Szentivanyi A. Effects of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophyl-line and its metabolites in rats. Biochem Pharmacol 1979; 28: 2935-2940.
21. Yu SY, Bae SK, Kim EJ, et al. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administrations to rats: gastrointestinal first-pass effect. J Pharm Sci 2003; 92: 1592-1603.
22. Nagase S, Shimamune K, Shumiya S. Albumin-deficient rat mutant: an animal model for analbuminemia. Exp Anim 1980; 29: 33-38.
23. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
24. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel-Dekker: New York, 1982.
25. Chiou WL. New calculation method of mean total body clearance of drugs and its application to rational dosage regimens. J Pharm Sci 1980; 69: 90-91.
26. Chiou WL. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
27. Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
28. 28 Csejke M, Schuller J. The binding of 5-fluorouracil to serum protein fractions, erythrocytes and ghosts under in vitro conditions. Arch Pharm (Weinheim) 1992; 325: 69-71.
29. Kim EJ, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous bumitanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm Drug dispos 2001;- 22: 147-156.
30. Takada K, Kawamura T, Inai M, et al. Pharmacokinetics of cisplatin in analbuminemic rats. Biopharm Drug Dispos 1999; 20: 421-428.
31. Celio LA, Digregorio GJ, Ruch E, Pace JN, Piraino AJ. 5-Fluorouracil concentration in rat plasma, parotid saliva, and bile and protein binding in rat plasma. J Pharm Sci 1983; 72: 597-599.
32. Haggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-2206.
33. Gustavsson BG, Brandberg A, Regardh CG, Almersjo OE. Regional and systemic serum concentrations of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs. J Pharmacokinet Biopharm 1979; 7: 665-673.
34. Nagase S, Shimamune K, Shumiya S. Albumin deficient rat mutant. Science 1979; 205: 590-591.